Research

Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma
Cancer Cell. November 2022.

Single Cell Characterization of Myeloma and its Precursor Conditions Reveals Transcriptional Signatures of Early Tumorigenesis​
Nature Communications. November 2022.

Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes
Nature Communications. June 2022.

Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study
Lancet Haematology. May 2022.

Quality of life, psychological distress, and prognostic perceptions in patients with multiple myeloma
Cancer. Feb 2022.

Attenuated response to SARS-CoV-2 vaccine in patients with asymptomatic precursor stages of multiple myeloma and Waldenstrom macroglobulinemia​
Cancer Cell. Jan 2022.

​ASH Abstracts (December 2022)

Single-Cell RNA-Sequencing of 245 Tumor Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveals Novel Insights into Malignant Plasma Cell Biology
Junko Tsuji et al.

Single-Cell RNA-Sequencing Identifies Immune Biomarkers of Progression in Patients with High-Risk Smoldering Multiple Myeloma Treated with Immunotherapy
Romanos Sklavenitis-Pistofidis et al.

High-Throughput Plasma Proteomic Profiling to Identify Candidate High-Risk Disease Biomarkers in Precursor Multiple Myeloma Patients
Elizabeth Lightbody et al.

Single-Cell RNA Sequencing of Rare Circulating Tumor Cells in Precursor Myeloma Patients Reveals Molecular Underpinnings of Tumor Cell Circulation
​Elizabeth Lightbody et al.

Monitoring Plasma Cells and Clonal Emergence through Genome Sequencing of Circulating Tumor Cells for Minimally Invasive Molecular Characterization of Multiple Myeloma
​Ankit Dutta et al.

Isatuximab in Combination with Lenalidomide and Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma: Updated Safety Run-in Results from the Randomized Phase 3 Ithaca Study
Maria-Victoria Mateos et al.

In Situ Characterization of Chromatin Landscape in Progression of Smoldering Precursor Stage to Multiple Myeloma
​Mahshid Rahmat et al.

Dysregulated Humoral and Cellular Response to Sars-Cov-2 Vaccination in Patients with MGUS and SMM
​Yoshi Konishi et al.

Reconstructing the Genomic History of Multiple Myeloma Precursor Disease: Novel Insights and Clinical Applicability
​JB Alberge et al.

​Abnormal Free Light Chains in Individuals with African Ancestry Screened for Monoclonal Gammopathy: Definition of New Reference Range Accounting for Renal Function and Race
​Luca Bertamini et al.

Persistence of Monoclonal Gammopathies in Serial Samples from a US Population-Based Screening Study
Habib El-Koury et al.

Prevalence of Monoclonal Gammopathies Detected By Mass Spectrometry and Their Risk Factors Among Black Africans in South Africa
​David J. Lee et al.

Inhibition of MICA and MICB Shedding Enhances Cytokine-Induced Memory-like NK Cell-Mediated Activity Against Multiple Myeloma
​Sabrin Tahri et al.

Single-Cell RNA-Sequencing of 370 Bone Marrow and Peripheral Blood Immune Cell Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveal Significant Immune Dysregulation at the MGUS Stage, and Novel Interactions between Tumor and Immune Cells
​Romanos Sklavenitis-Pistofidis et al.

​Reviews & Protocols

Mass cytometry staining for human bone marrow clinical samples
STAR Protocol; Cell Press. March 2022.

Single-cell profiling of tumour evolution in multiple myeloma - opportunities for precision medicine
Nature Reviews Clinical Oncology. Jan 2022.